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ABSTRACT 
 
 
ABUNADA, TAGHREED, H. A., Masters of Science:  
June : 2018, Biomedical Sciences 
Title: NATIONAL STUDY OF ANAPHYLAXIS IN A LARGE TERTIARY CARE HOSPITAL IN QATAR: A 
RETROSPECTIVE STUDY-  
Supervisor ofThesis: Dr. Hatem Z. Ibrahim. 
 
Background: Anaphylaxis is a serious systemic allergic disease that often mani-
fests with a broad array of symptoms and leads to death if not immediately treated by the 
administration of epinephrine auto-injector (EAI). Aims and objectives: To assess EAI 
dispense as an indicator to estimate anaphylaxis in Qatar, to determine the common causes 
of anaphylaxis in Qatar, to dissect the clinical profile of patients, and to determine the 
comorbidity factors in patients with anaphylaxis in Qatar. Methods: A retrospective study 
conducted using 1,068 electronic medical records (EMR) of anaphylaxis patients through 
the period of 2012 to 2016. The majority of the patients were collected from dispensed 
EAIs of outpatients (622) and the remainder (446) were from ICD-10 codes.  To assess the 
feasibility of using the dispensed EAIs as possible measure for anaphylaxis, we calculated 
the sensitivity and specificity of this test on our patients’ cohort (1,068). The demographics 
data, triggers, co-morbidity factors, symptoms, and clinical manifestations were catego-
rized and thoroughly analyzed. Statistical analysis was performed with version 24 SPSS 
statistic software package. Results: The sensitivity of dispensed EAIs to detect anaphylaxis 
was 87.0% with positive predictive value (PPV) of 80%. There were 574 patients (53.5%) 
diagnosed with anaphylaxis, male to female ratio was 1.2, and 300 patients (77.9%) were 
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less than ten years. Food was the leading trigger of anaphylaxis (n=316, 55.0%) followed 
by insect stings (n=161, 28.0%) and drugs (n=103, 17.9%). Asthma (n=208, 36.2%), atopic 
dermatitis (n= 195, 33.9%) and allergic rhinitis (n=81, 14.1%) were the common comor-
bidity factors that significantly associated with anaphylaxis. Symptoms included 87.9% 
cutaneous, 69.1% respiratory, 47.5% gastrointestinal, 15.8% cardiac, and 8.8% neurologi-
cal. Patients treated without the use of EAIs (n=143, 77.7%) were exposed to more serious 
adverse events including two deaths and one shock. Conclusion: This study will serve as 
a clinical guide for clinicians at allergic and pediatrics clinics and might be used as a base-
line to assess the future trend of anaphylaxis in Qatar. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction 
 
 
Anaphylaxis is a severe systemic allergic reaction associated with different triggers, 
clinical presentations, co-morbidity factors and clinical outcomes. Allergens such as 
food, drugs, and venom insects trigger the onset of anaphylaxis, and can rapidly pro-
gress in unpredictable manner to life-threating complications or even death within 
minutes if not recognized and treated immediately. Anaphylactic reactions usually oc-
cur when the patients are in the community away from clinical settings. Therefore, 
early self-administration of epinephrine in the form of EAI is essential to save the pa-
tient life and avoid the culprit lifelong complications of anaphylaxis.  
 
Characterization of anaphylaxis is crucial in term of its triggers, clinical presenta-
tion, risk factors, and clinical outcome of patients especially with the limited number 
of published case reports and studies in Qatar. For instance, two cases of food-depend-
ent exercise-induced anaphylaxis have been reported and managed successfully (1). 
Another study reported delayed clavulanic acid-induced anaphylaxis in a patient during 
bariatric surgery (2). In a prospective cohort study conducted between 2007 and 2010 
on 38 children to assess cow’s milk allergy, 29 children (76.3%) presented with ana-
phylactic episodes (3). Two recent abstracts also highlighted the incidence of anaphy-
laxis among children and adults in Qatar (4, 5).  EAIs are dispensed in the form of 
Epipen by Hamad General Hospital to all over other hospitals and health centers in 
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Qatar. Therefore, we believe that EAI dispense is a useful indicator to estimate the 
frequency of anaphylaxis and characterize it in Qatar which might act as a clinical guide 
for allergic clinics in Qatar. 
 
1.2 Hypothesis 
 
The primary hypothesis is that epinephrine auto-injector (EAI) dispense is a meas-
uring tool to characterize anaphylaxis in Qatar. The secondary hypothesis is that pa-
tients treated with epinephrine auto-injectors will have no serious adverse events. 
 
1.3 Aim 
 
This study aimed to investigate EAI dispense as a clinical indicator to estimate an-
aphylaxis in Qatar. 
 
1.4 Objectives 
 
 
1. To estimate anaphylaxis in Qatar in the period of 2012 – 2016. 
2. To determine the most common triggers of anaphylaxis in Qatar according to gen-
der, age, and nationality 
3. To characterize the most common clinical symptoms and co-morbidity factors as-
sociated with anaphylaxis in Qatar. 
4. To define the outcome of anaphylaxis among patients who treated with and without 
EAIs. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Definition of Anaphylaxis  
 
The term “anaphylaxis” was introduced in 1901 to describe a phenomenon of in-
creased sensitivity resulted in the death of an experimental animal (dog) after re-admin-
istration of the venom of anemone species (6).  Because the result of the experiment was 
opposite to the scientists’ intention to immunize the dog, the phenomenon was called “an-
aphylaxis” (“ana” means “against” or “opposite”, and “phylaxis” means “protection” in 
Greek) (6, 7). Whether the same phenomenon occurred in human beings or not was in 
doubt until 1945; when increased use of medications resulted in recognition of anaphylaxis 
in human beings as well (6). Despite such recognition, there was no consensus over the 
definition of anaphylaxis and its treatment among physicians, which imposed National In-
stitute of Health (NIH), and Food Allergy and Asthma Network (FAAN) to recruit an in-
ternational panel of physicians from North America, Europe, and Australia who established 
consistent, clinically relevant criteria to diagnose anaphylaxis (2005 – 2006)(6). Following 
this international consensus, many independent guidelines of anaphylaxis management 
were published during the period from 2010 to 2014 by four allergy/immunology organi-
zations : World Allergy Organization (WAO), American Academy of Allergy, Asthma and 
Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology 
(ACAAI) and the European Academy of Allergy and Clinical Immunology (EAACI) (8). 
Accordingly, anaphylaxis is currently defined as “a serious, generalized or systemic, al-
lergic or hypersensitivity reaction that can be life-threatening or fatal” (6, 8-10).   
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2.2 Diagnosis Criteria of Anaphylaxis 
 
Diagnosis of anaphylaxis is likely when any one of the following criteria is fulfilled:  
Criterion 1. Acute onset of illness (minutes to several hours) with involvement of the skin, 
mucosal tissue or both accompanied with either respiratory compromise or reduced blood 
pressure or associated symptoms of end-organ dysfunction (11-13). 
Criterion 2. Involvement of two or more systems that occur rapidly following the exposure 
to a likely allergen. Systems that might be involved include skin-mucosal tissues, respira-
tory compromise, reduced blood pressure and associated symptoms, or persistent gastroin-
testinal symptoms. A likely allergen is a substance that (i) the patient exposed to it before 
the development of symptoms; (ii) deemed as the cause of anaphylaxis by attending phy-
sician and did not induce a previous known reaction (11-13). 
Criterion 3. Reduced blood pressure after exposure to a known allergen.   This definition 
considers blood pressure as “reduced”, in general, if it is lower by 30% than the patient’s 
baseline (11-13). The definition also specifies reduced blood pressure based on patient’s 
age as the following: (i) For adults and adolescents (11-17 years): Systolic blood pressure 
is less than 90 mmHg, (ii) For children (1-11 years):  Systolic blood pressure is less than 
(70 mmHg + [2*age]), (iii) For infants (1 month – 1 Year): Less than 70 mmHg.    
 
Despite that these criteria are likely to capture more than 95% of anaphylactic cases, 
patients may present with unusual symptoms which make the diagnosis of anaphylaxis 
difficult for clinicians (14). In Qatar, expert physicians in the field of immunology and 
allergy at HMC developed two anaphylaxis clinical protocols: one for pediatrics (CPRO 
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10550, Year: 2016) and another one for adults (CPRO 10538, Year: 2014). These two clin-
ical protocols are in accordance with the international guidelines and are available online 
for HMC clinicians.  
 
2.3 Pathophysiology of Anaphylaxis 
 
Anaphylaxis is divided in to “allergic anaphylaxis” mediated by an immunological 
mechanism and “non-allergic anaphylaxis” mediated by a non-immunological mechanism 
(15). Idiopathic anaphylaxis is a third category suggested by Simons et al. (2006) because 
considerable number of anaphylactic cases are not easily to be included in any one of the 
previous two categories. 
 
Introducing the allergen directly to the blood stream initiates anaphylaxis in sensi-
tized individuals. In the classical pathway of IgE-mediated anaphylaxis, the major anaphy-
laxis patho-mechanism, the allergen-specific IgE antibody is bounded to the membrane of 
mast cells and basophils through its high affinity receptor (mainly FcεRI). Binding of the 
allergen to the allergen-specific IgE antibody results in cross-linking of its receptor FcεRI, 
its aggregation and activation of the mast cells and basophils. This leads to degranulation 
and release of potent mediators, which act directly on different tissues, recruit other in-
flammatory cells and amplify the allergic symptoms (9, 10, 16). Histamine, tryptase, leu-
kotrienes, and platelets activating factors are the most potent mediators of IgE-mediated 
anaphylaxis (16).  
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On the other hand, alternative pathways of anaphylaxis are less common in human 
subjects compared to the classical pathway (17). These pathways include IgG and comple-
ment mediated anaphylaxis. In IgG-mediated anaphylaxis, the reaction is mediated by 
IgG/allergen complex that crosslink Fc gamma receptors (FcγRs) on macrophages, baso-
phils and neutrophils. The IgG/allergen complex has higher affinity than monomeric IgG 
antibody to FcγRs and can therefore displace it to activate these receptors (16-18). Herein, 
the platelet-activating factor, produced from neutrophils, is the predominant released me-
diator not the histamine (16). Augmentation of such hypersensitivity responses is associ-
ated with the release of C3a complement (16). Some cases of anaphylaxis after the admin-
istration of monoclonal antibodies (mAbs) without detectable anti-drug IgE support the 
presence of IgG mediated mechanism in human subjects (19) . In complement-induced 
anaphylaxis, complement-derived peptides C3a, C5a and C5b9 mediate anaphylaxis in the 
absence of immune complex by direct binding to their specific receptors on mast cells, 
basophils, and other myeloid cells (16, 17). The re-exposure response for allergen in such 
direct complement-induced anaphylaxis is milder than the first time exposure (16). In sup-
port to complement mediated anaphylaxis mechanism, studies showed immediate wheal-
and-flare reactions after the injection of low doses of C3s, C4a or C5a in the skin of healthy 
volunteers (19). Moreover, the concentration of these complements in blood correlate with 
the severity of anaphylaxis in human subjects (19). 
 
Non-immunologic anaphylaxis involves mast cell mediator release due to cold tem-
perature exposure, exercise or from medications such as opioids or vancomycin (20). This 
type of anaphylaxis is under-reported in the literature and the exact mechanism is unknown.  
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2.4 Potential Mediators of Anaphylaxis 
 
The pathophysiological activities and clinical manifestation of anaphylaxis depends 
on the effect of mediators released from mast cells and other immune cells at the time of 
anaphylaxis and their subsequent binding to specific tissue receptors on the target organ(s) 
affected (21). Such mediators of anaphylaxis are as listed below: 
 
 Tryptase.  Tryptase is stored in the granules of mast cell and basophiles and 
released from them upon their activation and degranulation. It peaks in the blood of human 
subjects within 60 to 90 minutes after the anaphylactic symptoms onset. This increase of 
tryptase level is temporary and resolve within 24 -48 hours (21). Therefore, tryptase is the 
most widely used biomarker to confirm anaphylaxis retrospectively (19, 22). Tryptase 
plays a role in airway homeostasis, vascular relaxation and contraction, gastrointestinal 
smooth muscle activity, intestinal transport, and coagulation (23). It activates matrix met-
alloproteinases and initiates connective tissue matrix remolding or disintegration (24). 
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 Histamine. The main source of histamine is mast cells and basophiles (19). There 
are four known histamine receptors: H1, H2, H3 and H4 (19). Histamine release and its 
subsequent binding to H1 receptors leads to coronary vasoconstriction and bronchial con-
striction while its binding to H2 receptors induces systemic vasodilation, gastric acid se-
cretion, and cardiac contractility (10, 25). Both H1 and H3 receptors modulate nasal con-
gestion, cutaneous itching and the characteristic wheal-and flare reaction of anaphylaxis 
(10, 25) . Histamine levels rise 5 to 10 minutes after the onset of anaphylaxis and returns 
to normal within 60 minutes (19).  
 
Platelet activating factor (PAF). Platelets activating factor (PAF) is a potent phos-
pholipid-derived mediator (19, 26). Cells that produce and respond to PAF include plate-
lets, mast cells, neutrophils and macrophage (19). PAF induces platelets aggregation and 
activation. It results in increased vascular permeability, circulatory collapse, and decreased 
cardiac output. Recent studies showed that Platelets activating factor correlates inversely 
to the severity of anaphylaxis reaction (26).  
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Leukotrienes and prostaglandin.  Leukotrienes are lipid mediators that are syn-
thesized in the leukocytes from arachidonic acid (AA) via the actions of 5-lipoxygenase 
(5-LO). They are divided into two classes: LTB4 and cysteinyl leukotrienes. LTB4 is a 
potent chemoattractant for leukocytes and plays an important role in activating phagocytic 
cells, differentiated T-cells and dendritic cells. On the other hand, cysteinyl leukotrienes 
such as LTCs, LTDs, and LTE4 were known previously as “slow-reacting substance of 
anaphylaxis” Their pathophysiological role in anaphylaxis result in mast cell activation and 
vascular permeability. Moreover, studies show that cysteinyl leukotrienes have potent 
bronchoconstriction effect in asthma patients (27). 
 
2.5 Signs and Symptoms of Anaphylaxis 
 
Clinical manifestation of the patient is the gold standard to diagnose anaphylaxis. 
The symptoms are heterogonous in nature and variable. Anaphylaxis can begin with rela-
tively minor symptoms and progress in unpredictable manner to a life-threatening reactions 
(14). Organs that are affected by anaphylaxis include skin (90%), respiratory (70%), gas-
trointestinal (30 -45%), cardiovascular (35%) and central nervous system (10 -15%) (9, 
28).  
The signs and symptoms of anaphylaxis include the below symptoms (12, 28, 29): 
1. Skins symptoms such as rash, itching, erythema, urticaria, swelling of 
the face, lips and periorbital area.  
2. Respiratory symptoms such as nasal congestion, rhinorrhea, throat itch-
ing, laryngeal edema, stridor, choking, wheezing, cough and dyspnea. 
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3. Gastrointestinal symptoms such as vomiting, abdominal cramping, nau-
sea and diarrhea. 
4. Cardiovascular symptoms such as tachycardia, hypotension and hypo-
tonia. 
5. Central nervous symptoms such as anxiety, mental confusion and sei-
zures.  
 
Despite of the presence of the diagnostic criteria and guidelines for clinicians, ana-
phylaxis is often under-recognized especially if cutaneous symptoms are absent (20% of 
the cases) (30). Moreover, atypical symptoms of anaphylaxis start to emerge and they in-
clude fever and chills without apparent involvement of IgE mediated mechanisms (21). 
Severity of anaphylaxis varies from episode to episode even with identical stimulus in the 
same patients (14). Cox et al. (2017) suggested a new modified grading system for systemic 
allergic reaction that might enhance recognition of mild systemic allergic reactions apart 
from anaphylaxis and allow better classification of anaphylaxis in clinical trials and sur-
veillance studies (31). In general, anaphylaxis has three patterns based on disease manifes-
tation (28).  
1. Uniphasic anaphylaxis: It accounts for 70% -90% of anaphylactic cases. 
The symptoms peak within 30 -60 minutes from exposure for the aller-
gen trigger. It is not recurrent once it is resolved. 
2. Biphasic anaphylaxis: It accounts for 1% - 23% of anaphylactic cases. 
Usually the symptoms peak within hours. The symptoms re-occur 
within eight hours without re-exposure to the allergen trigger. 
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3. Protracted anaphylaxis: It is rare and symptoms might become persis-
tent for days and weeks.  
Failure to give optimal dose of epinephrine initially may be associated with increased risk 
of biphasic anaphylaxis (14). 
 
2.6 Triggers of Anaphylaxis 
 
Triggers of anaphylaxis are variable in the community (9). The intrinsic character-
istics of the trigger, its dose and the patients’ associated co-morbidity factors determine the 
severity of the anaphylactic reaction (16). In general, any agent that is capable of producing 
a sudden degranulation of mast cells or basophils can induce or trigger anaphylaxis(14). 
Among biological triggers, food especially peanut, tree nut, shellfish, cow’s milk and egg 
are common in children while drugs and insect stings are more common in adults (9). Some 
reports show evidence of anaphylaxis due to whole seminal fluids in females (32, 33). 
Moreover, progesterone surge is currently considered as a trigger of anaphylaxis in females 
presenting with catamenial anaphylaxis before and during their menstrual cycles (21). 
Some studies indicate anaphylaxis due to vaccines and intravenous immunoglobulin (34-
36). Physical triggers of anaphylaxis include cold and exercise. In some patients, exercise 
alone can’t initiate anaphylaxis rather than combination of exercise and food ingestion (9). 
In other cases, the trigger remains idiopathic.  
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2.7 Risk Factors and Comorbidity Associated with Anaphylaxis 
 
Some co-morbidity factors worsen the outcome of the anaphylactic reaction for the 
patient if synchronized with the anaphylaxis onset. Examples include asthma, atopic der-
matitis, allergic rhinitis, frequent infections, other respiratory tract disorders, cardiovascu-
lar diseases and mastocytosis (9, 37).  
 
Asthma. Asthma is a chronic lung disease that results from inflammation and nar-
rowing of airway tubes leading to shortness of breath, frequent wheezing, chest tightness 
and coughing. According to the World Health Organization (WHO), approximately 235 
million people worldwide have asthma. The disease is most common in children 
(http://www.who.int/respiratory/asthma/en/). Several studies highlight asthma as a risk 
factor that can worsen the outcome of anaphylactic reaction and induce death in adolescents 
and young adults (12, 28). Analysis of United Kingdom national anaphylaxis data over 20-
year period (1992-2012) stated that 78% of 124 fatal cases of anaphylaxis were in patients 
with a physician's diagnosis of asthma (38).  
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Atopy. Atopy is the genetic tendency to develop allergic disease (15, 39). Consid-
ering atopy as a risk factor for anaphylaxis depends on the type of antigen involved, route 
of administration and sensitization (15, 39) . Atopic individuals especially in response to 
inhalant and food triggers are at increased risk of having anaphylaxis (15, 20). Such pre-
disposition to anaphylaxis is not justifiable by the increase levels of IgE alone since many 
atopic individuals with elevated IgE to food, inhalant and insect venom fail to develop 
anaphylaxis on exposure and during immunotherapy (15). Therefore, it is believed that 
additional factors account for anaphylaxis in atopic individuals (15).  
 
Mastocytosis. About 30% of patients having mastocytosis due to the somatic  mu-
tation KIT (D816V) can show unprovoked anaphylaxis (21). This mutation is responsible 
for constitutive KIT receptor activation on mast cells even in the absence of its correspond-
ing ligand (Stem cell factor) leading to intensive release of mast cell mediators (40).   
 
2.8 Incidence of Anaphylaxis 
 
The incidence of anaphylaxis is difficult to characterize due to the transient acute 
nature of the disease (39). However, data from hospital admission rates indicates that ana-
phylaxis is common and had increased in the UK, USA, Canada and Australia over the last 
10 -20  years (41). Most studies depend on self-report, medical coding systems, epinephrine 
dispense rate, or hospital admission rate to gather data that characterize anaphylaxis (41). 
Below is a list of some retrieved studies of reported incidence of anaphylaxis in the world.  
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Table 1 
Reported Anaphylaxis Cases in Different Countries 
Abbreviations: NA= not applicable, NR= not reported 
 
Country Study Type Study period M:F 
 ratio 
Age (Y)  Screened 
Patients 
Anaphylaxis 
cases 
Reference 
USA Retrospective 
cohort  
2007 -2012 1.50 0.5 - 18  7303 5947 (42) 
Retrospective  2009 - 2010 0.58 0 - 65  122 77 (43) 
Retrospective  2008 -2010 1.46 0 - 21  313 43 (44) 
Prospective  - 1.65 3.4 - 13.5 186 53 (45) 
Case Report  NA 71  1 1 (46) 
Retrospective  2004 - 2008 0.84 0.33 - 18  213 192 (47) 
Retrospective  2005 - 2006 0.74 0 - 85 3024 2751 (48) 
Retrospective  2001 - 2006 1.63 5.9 - 7.4 1255 685 (49) 
Retrospective  1999 -2007 1.37 5 - 10.5 436 79 (50) 
Retrospective  1990 - 2000 0.79 0.8 - 78.2 211 211 (51) 
Retrospective  Jan-July, 
2012 
0.52 37.9 - 
69.7 
11761 92 (52) 
Retrospective 
cross sec-
tional  
2009 - 2013 1.34 2.6 - 12.0 10351 10442 (53) 
Case Report - NA 50 1 1 (54) 
Retrospective  2009 - 2013 1.28 5.9 10442 5203 (55) 
Retrospective  1999 - 2010 1.19 20 - 73 2,458 2,458 (56)  
Case report 1994 NA 67 1 1 (57) 
UK Retrospective 2013 - 2016 0.63 18 - 83 31 31 (58) 
Retrospective 
cohort study  
10 Years 0.92 
30.3 - 
60.9 
761 340 
(59) 
Retrospective  2005 – 2009 0.55 0 -85 537,605 ad-
missions 
1350 (60) 
Case report 2011 NA 25 1 1 (61) 
Retrospective  2005 -2012 0.33 35 -65 NR 161 (62) 
UK/ 
Ireland 
Retrospective 2008 - 2009 NR 0 - 16 15 7 (63) 
Qatar Case report 2009 & 2011 1 14 – 15 2 2 (1) 
Prospective 
cohort study 
2007- 2010 1.92 0.2 – 10.5 35 9 (64) 
Clinical pilot 
study 
2007- 2010 1.92 0 - 14 38 10 (3) 
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Continue Table 1 
Reported Anaphylaxis Cases in Different Countries 
Abbreviations: NA= not applicable, NR= not reported 
 
 
 
Country Study Type Study period M:F 
 ratio 
Age (Y)  Screened 
Patients 
Anaphylaxis 
cases 
Reference 
UAE Cross sec-
tional 
2006 0.94 6.1 – 8.3 397 143 (65) 
Cross sec-
tional 
NR 0.24 18 – 76 177 94 (66) 
Case report 2010 NA 6 1 1 (67) 
KSA Case report 2016 NA 6 1 1 (68) 
Case report 2017 NA 19 1 1 (69) 
        
KSA Retrospective  2010 – 2011 0.93 Child ≤ 18 
Adult > 
18 
238 238 (70) 
Retrospective  1 year 1.26 18 - 70 43 1 (71) 
 
Case report 2014 NA 12 1 1 (72) 
Case report 2013 NA 62 1 1 (73) 
Case report 2010 NA 4 1 1 (74) 
Case report 2010 NA 5 1 1 (75) 
Case report 2006 NA 32 1 1 (76) 
Case report 1997 NA 36 1 1 (77) 
Case report 1995 NA 34 1 1 (78) 
Kuwait Survey 2017 0.29 0 - 19 865 20 (79) 
Lebanon Case report 1997 NA 18 1 1 (80) 
Cross sec-
tional 
1 year NA NR 1842 23 (81) 
Retrospective 
study 
2009 NA NR 245 39 (82) 
Survey ques-
tionnaire 
2014 0.54 Child ≤ 14  
Adult > 
14 
506 55 (83) 
Algeria Case report 2005 NA 4 1 1 (84) 
Turkey Retrospective  2008 -2011  Adults 24,443 ad-
missions 
516 (85) 
Portugal Case report 2008 NA 18 1 1 (86) 
 Survey ques-
tionnaire 
2007 – 2010 0.5 2 - 89 313 313 (87) 
Spain Observational 
study 
2013 – 2015 1.01 12 – 47 277 55 (88) 
Thailand Observational 
cohort study 
2004 – 2008 1.12 0.1 - 70 208 208 (89) 
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2.8 Treatment of Anaphylaxis 
 
Anaphylaxis can rapidly progress in unpredictable manner to lead to life-threating 
complications or even death if not immediately recognized.  Delaying the treatment until 
the development of multi-organ symptoms is risky if not lethal (14). Successful manage-
ment depends on removal of potential trigger (if possible) and placing the patient in a 
recumbent position (if tolerated). ABCDE approach is used as soon as anaphylaxis is 
recognized to assess the patient’s airway, breathing, circulation, disability and skin reac-
tions (11). Administration of IV fluids with isotonic crystalloid fluid is essential as soon 
as possible for volume resuscitation. 
 
2.8.1 Immediate First Line Intervention Measures 
 
First-line intervention to treat anaphylaxis is the administration of epinephrine 
(adrenaline) (14). Epinephrine (adrenaline) is a cathecolamine that is naturally released 
from the neurons and the medulla of adrenal gland in response to exertion or stress. It has  
a molecular weight of C9H13NO3 with relative molecular mass of 183.2 (90, 91).  
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Figure 1. Epinephrine (adrenaline) graphic formula. (90) 
 
 
 
Epinephrine (adrenaline) discovery as a drug and its subsequent applications in 
medicine was the fruitful effort of many scientists in the latter half of the 19th century. 
George Oliver, a general practioner in Harrogate, North Yorkshire discovered that adrenal 
extract rise the blood pressure (92). In 1895, he proved with the assistance of Professor 
Edward Schafer, a physiologist at University College London, that this adrenal extract con-
stricted blood vessels and enhanced ventricle constriction by an active component from 
adrenal medulla not the cortex (92).  However, crude extract induced some allergic reac-
tions. Therefore, trials to identify and purify this vasoactive component were intensified. 
Otto von Furth in Strasbourg isolated a substance and called it suprarenin while John Ja-
cobs Abel, of Johns Hopkins University isolated a slightly different substance and called it 
epinephrine (92). Despite the fact that these substances were vasoactive, none of them 
proved to be adrenaline. In 1900, a pure crystalline substance from the adrenal medulla that 
is 2000 times stronger was isolated and purified by the Japanese chemist, Jokichi Takamine 
in cooperation with Parke, Davis and Co Laboratories (92). Takamine’s pure crystalline 
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had the trademark of adrenaline in 1901. Without regulatory authorities at that time, adren-
aline found its way in many medical applications mainly to stop bleeding. Physicians’ 
demonstration that it improved allergic diseases such as allergic rhinitis hives and asthma 
resulted in extensive studies about its therapeutic action (92). 
 
Epinephrine exerts its therapeutic action via its effect on α- and β- adrenergic re-
ceptors. Its effect on α1-adrenergic agonist receptors induces vasoconstriction, increases 
peripheral vascular resistance, and decrease mucosal edema (10, 14). It increases inotropy 
and chronotropy via β1-adrenergic agonist receptors while it induces bronchodialation and 
decreases inflammatory mediators released from mast cells and basophils via β2-adrenergic 
agonist receptors (10, 14, 25, 93). 
 
Route of administration and proper dose is significant to achieve the optimal ther-
apeutic effect and to avoid the occurrence of biphasic anaphylaxis (14). Administration of 
epinephrine intramuscularly in the anterolateral thigh provides complete rapid absorption 
and is preferred over subcutaneous or intravenous routes (9, 10, 14). Currently, EAIs are 
available as pre filled epinephrine auto-injecting devices such as Epipen® (Dey, LP, Napa, 
CA, USA), Anapen® (Lincoln Medical, Salisbury, Wiltshire, UK), Twinject® (Shionogi 
& Co., Ltd., Osaka, Japan) and Adrenaclick® (Shionogi Pharma, Inc., Atlanta,GA, USA) 
(94, 95). Two fixed doses of EAIs are available: 0.15 mg for children who weigh 10 -25  
Kg and 0.3 mg for children who weigh more than 25 Kg and adults (14, 30). Pharmacoki-
netic studies show that 8 minutes are required for epinephrine to reach a maximum con-
centration in plasma (2.136 pg/mL) after the intramuscular injection (96).  Such finding 
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correlates with the pharmacodynamics evidence of increase blood pressure and heart rate 
within 10 minutes of epinephrine injection (96). Repeating the epinephrine dose is possible 
every 5 - 15 minutes and depends on the severity of the anaphylactic reaction (14).  
 
Epinephrine has a narrow therapeutic window (14).  Adverse effects of epinephrine 
at recommended doses as well as over dosage do not absolutely contraindicate epinephrine 
administration in case of anaphylaxis (14, 25, 97, 98). Usual adverse effects include agita-
tion, anxiety, headache, dizziness, pallor, or palpitation. Rarely myocardial  ischemia, in-
fraction or intracranial hemorrhage may occur (14). Special care should be maintained 
when epinephrine is given for individuals who have increased number of β-adrenergic re-
ceptors in their vasculature system such as individuals with untreated hyperthyroidism be-
cause expected strong effect of epinephrine on the heart (14). However, the benefits of 
using epinephrine far outweigh the risks in an  anaphylactic reaction and prompt admin-
istration of it can be life-saving (39). Ideally, patients at risk of developing anaphylaxis 
should receive epinephrine  auto-injectors and referred to allergist or immunologist for 
further investigation (14).   
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Figure 2. Therapeutic window of epinephrine. (14) 
 
 
2.8.2 Second Line Intervention Measures 
 
The second line intervention includes H1-antihistamines, H2-antihestaminss corti-
costeroids, and beta-2 agonists (39). H1 antihistamines (e.g. diphenhydramine, fexofena-
dine, hydroxyzine,  cetirizine) decrease skin symptoms such as itching, erythema, and ur-
ticaria but they do not treat airway obstruction or hypotension in similar manner to epi-
nephrine (97). In combination to H1-antihistamines, H2 antihistamines (e.g. ranitidine) are 
effective at reducing hives and tachycardia but have no significant effect on itching symp-
toms (25). β2 agonist bronchodilator induces and improve the symptoms of respiratory dis-
tress by relaxation of  bronchial smooth muscles (99) . Corticosteroids are in use to prevent 
biphasic anaphylaxis (25). Corticosteroids switch off transcription of activated genes that 
encode pro-inflammatory proteins and decrease late phase allergic response (11). 
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These drugs are inferior to epinephrine and should never replace epinephrine since 
they are not life-saving and could not alone resolve the serious consequences of anaphy-
laxis (25). However, despite the fact that antihistamines have slow absorption and require 
1 – 3 hours for maximum plasma concentration after oral administration, data shows their 
frequent use rather than epinephrine to treat anaphylaxis (25). 
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CHAPTER 3: METHOD 
 
3.1 Data Collection 
 
This study was approved by the Medical Research Center, Hamad Medical Corpo-
ration in Qatar (HMC_IRB; 17122/17) for enrolment of 1,000 medical records (Appendix 
A: Approval of Research protocol # 17122/17).  
 
The EAI dispense records were collected from 2012 to 2016 from Hamad Medical 
Corporation. A total of 1,068 medical records were collected, 622 from the EAIs dispense 
list of HMC, and 446 from the medical coding system: the International Classification of 
Diseases, Tenth Revision, Australian Modification (ICD10AM) codes. The following 
codes were used to retrieve the data from the HMC medical registry: T78.0 Anaphylactic 
shock due to adverse food reaction; T78.1 Other adverse food reactions, not elsewhere 
classified; T78.2  Anaphylactic shock, unspecified; T80.5 Anaphylactic shock due to se-
rum; T88.6  Anaphylactic shock due to adverse effect of correct drug or medicament 
properly administered. Duplicates were removed after combing the two lists. The records 
were reviewed using Cerner Power-Chart system (Citrix XenApp, Cerner Millennium, 
USA). All patients’ data was collected anonymously to protect patients’ rights.  
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Figure 3. Flow chart of screened electronic medical records 
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3.2 Study Definitions  
 
Anaphylaxis was defined based on physician diagnosis and in accordance to the 
clinical criteria of anaphylaxis guidelines. Our inclusion criteria for Anaphylactic patients 
were either one of the following: (1) acute onset of illness (minutes to several hours) with 
involvement of the skin, mucosal tissue or both, and at least respiratory compromise or 
reduced blood pressure; (2) involvement of two or more systems out of four (skin-submu-
cosal tissue, respiratory, cardiovascular and gastrointestinal) in reactions that occur rapidly 
(minutes to several hours) after exposure to a likely allergen; or (3) reduced blood pressure 
after exposure to a known allergen (minutes to several hours). Allergy was identified as (1) 
patients who either have diseases other than anaphylaxis such as asthma, atopic dermatitis, 
urticaria, angioedema or allergic rhinitis; or (2) known triggers of allergic reaction and 
symptoms without fulfilling the clinical criteria of anaphylaxis. 
 
3.3 Clinical Data of the Study Population 
 
Electronic medical records were reviewed to collect patients’ demographics such 
as age, gender, nationality, and family history; characteristics of anaphylaxis events such 
as frequency of anaphylactic events, and symptoms where symptoms begin; characteristics 
of EAIs dispense such as frequency of dispense, times EAIs used by patients or others and 
indications of EAIs dispense; clinical presentation of anaphylaxis such as symptom related 
to skin, respiratory, gastrointestinal, cardiovascular and central nervous systems; anaphy-
laxis triggers such as food, drugs, venom insects, idiopathic or others; medical history;  
associated comorbidity factors thought to worsen the anaphylactic reaction; outcome of the 
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anaphylactic reaction when treated with or without EAIs, hospital admission, its duration 
(if any), associated complication and death occasions.   
 
Collected data was recorded in an approved data collection sheet (Appendix B: 
Data collection sheet). A standardized search method was used to extract the data from 
Cerner Power-Chart system as indicated below (Figure 4). 
 
 
 
Figure 4. The standardized search method in Cerner power-chart system 
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Confused/complicated cases were referred for allergy/immunology specialist in 
Hamad Medical Corporation. Collected data was abstracted into a spreadsheet using Mi-
crosoft Excel 2010 for analysis. 
 
3.4 Statistical Analysis 
 
Multi-variant statistical analysis using Statistical Package for Social Science 
(SPSS), Windows version 24 (SPSS Inc, Chicago, USA) was performed. Categorical var-
iables using frequency distributions, one and two-way tabulations, and percentages were 
summarized. Social demographics of the study population across groups, most common 
triggers, co-morbidity factors, symptoms and outcome were compared with a chi-square 
test. In 2 X 2 tables, the Fisher’s exact test (one- or two-tailed) replaced the chi-square in 
case of small sample size and where the expected frequency is less than 5 in any of the 
cells. The level where P-value < 0.05 was considered as significant. 
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CHAPTER 4: RESULTS 
 
4.1 Social Demographics of the Study Population 
 
Patients’ data (1,068) was collected from the electronic medical records of Hamad 
Medical Corporation from November 2012 to December 2016, of which 574 (53.5%) pa-
tients were diagnosed with anaphylaxis and 132 (12.3%) patients were with allergy (Table 
-1). Difference between patients with and without anaphylaxis was significant (P-value = 
0.009) in term of age and nationality, but insignificant in term of gender, family history 
and consanguinity. The incidence of anaphylaxis among children (<10 years) and adults 
(20 – 55 years) was the highest in Qatar followed by adolescents (10 – 19 years) and elderly 
(> 55 years) patients.  In Qatar, anaphylaxis was more common within male than female 
with a ratio of 1.2. Among anaphylaxis cases, there was one patient with no listed nation-
ality, 251 (43.7%) patients were Qatari, 162 (28.2%) patients were non-Qatari Arabs, and 
118 (20.5%) patients were Asian. There was limited number of patients registered with 
family history of atopy, diabetes mellitus, hypertension and anaphylaxis. The social de-
mographics of the study population in term of anaphylaxis were summarized below (Table 
2). 
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Table 2 
Social Demographics of the Study Population, N = 1068 
 
Abbreviations: DM = Diabetes Mellitus 
 Characteristics Total (n) Percent (%) Frequency, n (%) a P-value 
    Anaphylaxis 
(N=574) 
Allergy 
(N=132) 
 
Age (Years)      
 < 10 603 56.3 300 (77.9) 85 (22.1) 0.009 b 
 
 
 10 - 19 210 19.7 109 (83.2) 22 (16.8) 
 20 - 55 209 19.6 137 (86.7) 21 (13.3) 
 > 55 46 4.3 28 (87.5) 4 (12.5) 
Gender      
 Male 612 57.3 315 (79.1) 83 (20.9) 0.095 
 Female 456 42.7 259 (84.1) 49 (15.9) 
Nationality (N=1067) 
 Qatari 438 41.0 251 (79.9) 63 (20.1) 0.009 
 Non-Qatari, Arab 303 28.4 162 (86.6) 25 (13.4) 
 Asian 228 21.4 118 (83.1) 24 (16.9) 
 Others 98 9.2 42 (67.7) 20 (32.3)  
Family History (N = 123)      
 Atopy c 70 56.9 58 (87.9) 8 (12.1) 0.989 
 
 DM and/or hypertension 29 23.6 22 (88.0) 3 (12.0) 
 Other diseases 18 14.6 13 (86.7) 2 (13.3) 
 Anaphylaxis 6 4.9 5 (83.3) 1 (16.7) 
Consanguinity (N=33) 30 90.9 25 (92.6) 2(7.4) 1.000* 
a row percentage  
b Chi-Square for trend (linear by linear association) 
c Atopy includes asthma, atopic dermatitis, allergic rhinitis, and urticaria 
* P-value is for Fischer test (exact significant 2-sided) 
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4.2 Characterization of Anaphylaxis in the Study Population 
 
Medical records showed that patients had anaphylaxis multiple times in Qatar. 
Among recorded anaphylactic events, 48.3 % patients had anaphylaxis one time; 30.3 % 
patients had  it 2-3 times, while 2.7 % had more than three recorded anaphylactic events 
(Table 3) . Symptoms of anaphylaxis for about 507 (92%) patients began in the community. 
Community setting is a location other than a medical care facility such as home, school, 
street, party and restaurant. However, about 44 (7.9%) patients’ symptoms started inside 
hospitals, clinics and emergency department (Table 3).  
 
 
Table 3 
Characterization of Anaphylaxis in the Study Population, N = 706 
 
Abbreviations: ED= emergency department 
Characteristics Frequency (n) Percent (%) 
Anaphylaxis 574 81.3 
Frequency of anaphylaxis event    
 None 132 18.7 
 1 time  341 48.3 
 2 - 3 times 214 30.3 
 > 3 times 19 2.7 
Location where symptoms began (N=551)   
 Community 507 92.0 
 Inside hospital/clinic/ED 44 7.9 
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The patients’ outcome due to anaphylaxis was variable. About 360 (62.7%) of an-
aphylactic cases were admitted to the emergency department, of which 262 cases (24.5%) 
length of stay was less than 24-hours. Approximately half of the anaphylactic cases referred 
to the allergy and immunology clinics. Only 71 (12.4%) of anaphylactic cases required 
close regular monitoring as inpatient. Comparing severe adverse events across patients 
groups showed that anaphylactic patients who were more frequently associated with res-
piratory arrest (5, 0.9%), profound hypotension (3, 0.5%), and cardiac arrest (2, 0.3%).   
(Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Table 4 
Characteristics of Anaphylaxis Outcome in the Study Population, N =1068 
 
Abbreviations: ED = emergency department, LOS = length of stay, A/I = allergy and immunology 
                Anaphylaxis  
Patients' outcome All subjects Yes No   
 N=1068 N=574 N=132  
  n (%) n (%) n (%) P-value 
ED admission 576 (53.9) 360 (62.7) 9 (6.8) < 0.001 
ED LOS , N=372      
                  < 24 hours 262 (24.5) 253 (44.1) 9 (6.8) 0.070 trend 
                 24 -72 hours 71 (6.6) 71 (12.4) 0 (0.0)  
                 > 72 hours 39 (3.7) 39 (6.8) 0 (0.0)   
Referral to A/I clinic 630 (59.0) 293 (51.0) 66 (50.0) <0.001 
Admission as inpatient 568 (53.2) 71 (12.4) 1 (0.8) 0.157f 
Serious Adverse Event 22 (2.1) 22 (3.8) 0 (0.0) 0.264 
      Respiratory arrest 5 (0.5) 5 (0.9) 0 (0.0) * 
      Profound hypotension 3 (0.3) 3 (0.5) 0 (0.0) * 
      Cardiac arrest 2 (0.2) 2 (0.3) 0 (0.0) * 
      Death 2 (0.2) 2 (0.3) 0 (0.0) * 
      Endotracheal intubation 10 (0.9) 10 (1.7) 0 (0.0) * 
     Pulmonary edema 9 (0.8) 9 (1.6) 0 (0.0) * 
     Persistence of cutaneous man-
ifestations 
3 (0.3) 3 (0.5) 0 (0.0) * 
     Infection 2 (0.2) 2 (0.3) 0 (0.0) * 
     Sub conjunctival hemorrhage 1 (0.1) 1 (0.2) 0 (0.0) * 
     Shock 1 (0.1) 1 (0.2) 0 (0.0) * 
      Angioedema 3 (0.3) 3 (0.5) 0 (0.0) * 
  * P-value not calculated due to small sample size 
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4.3 Characterization of EAI Dispense in the Study Population 
 
Out of the 1,068 medical records, 739 (69%) patients had documented EAI dispense 
with anaphylaxis being the primary indication of EAIs dispense for 477 (64.5%) patients. 
Valid indications of EAIs dispense include asthma/allergy (16.5%), known fatal/near fatal 
food allergy (5.8%), and urticaria possible to prelude to anaphylaxis (2.97%). Other indi-
cations such as allergy, mucopolysacharidosis type IV, C1 esterase inhibitor deficiency 
counted for 3.5%. All patients received one or multiple EAIs dispense; however, only 89 
(12%) patients had documented EAIs use (Table 5).  
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Table 5 
Characterization of EAIs Dispense in the Study Population 
 
Characteristics Frequency (n) Percent (%) 
EAI dispensed 739 92.6 
     Indication of EAI dispensed*    
  Anaphylaxis (N=712) 477 67.0 
  Other indications (N=213)   
             Asthma & allergy 122 16.5 
             Known fatal / near fatal food allergy 43 5.8 
             Urticaria possible to prelude anaphylaxis 22 2.9 
             Others  26 3.5 
Frequency of EAI dispense , (N=996)   
 None  257 25.8 
 1  time  355 35.6 
 2 - 3 times 277 27.8 
 > 3 times 107 10.7 
EAI compliance*, (N= 464) 89 19.2 
EAI administered in community*, (N = 30)   
 Parents 20 66.7 
 Self 7 23.3 
 Others 3 10.0 
           *As listed in the electronic medical record of Cerner power chart system 
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4.4 Anaphylaxis versus EAIs Dispense 
 
 After reviewing the entire electronic medical records of 1,068 patients, data 
showed that 499 (71.1%) of patients who had anaphylaxis received EAIs, while 74 (10.5%) 
did not, 118 (16.8%) of patients who received EAIs had no anaphylaxis (Table 6). There 
were ten patients (1.4%) with neither anaphylaxis nor EAI. 
 
 
Table 6  
Epinephrine EAIs Dispense Against Anaphylaxis, N= 702 
 
Anaphylaxis        EAI Dispense, n (%) 
 Yes No 
Yes 499 (71.1) 74 (10.5) 
No 118 (16.8) 10 (1.4) 
 
 
 
In order to understand whether the EAIs dispense can be used as a measuring tool 
for anaphylaxis, we estimated the sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) for the 1,068 patients. The sensitivity of the EAIs 
dispense as indicator for anaphylaxis was 87% with PPV of 80%; however, the specificity 
was 8% with NPV of 11.9% (Figure 5).  
 
 
 
35 
 
 
 
 
Figure 5. The sensitivity (A) and specificity (B) of EAIs dispense for anaphylaxis. 
 
 
4.5 Common Triggers of Anaphylaxis in Qatar 
 
Most common of triggers of anaphylaxis in Qatar included food (316, 55.0%), 
venom insects (161, 28.0%) and drugs (103, 17.9 %). However, idiopathic triggers ac-
counted for 44 (7.6%) of the cases (Table 7 -9). 
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4.5.1 Food Triggers of Anaphylaxis in Qatar 
 
Among the most common trigger of anaphylaxis in Qatar, food was significantly 
associated with 316 (55.0%) of the cases. Dry fruits triggers such as nuts, cashew, pistachio 
and tree nuts were responsible for 173 (30.1%) of the cases. Other food triggers include 
egg (15.5%), seafood (12.5%), peanuts (12.3%), cow’s milk (10.6%), sesame seeds (8.7%), 
and wheat (6.1%) (Table 7). 
 
 
Table 7  
Most Common Food Triggers of Anaphylaxis in Qatar, N = 1068 
 
Triggers All  subjects  
N = 1068 
n (%) 
Anaphylaxis 
N= 574 
n (%) 
Allergy 
N= 132 
n(%) 
P-value 
Food (All) 403  316 (55.0 ) 87 (65.9) < 0.001 
Nuts a 232 173 (30.1) 59 (44.6) < 0.001 
Egg 113 89 (15.5) 24 (18.1) 0.171 
Seafood 93 72 (12.5) 21 (15.9) 0.111 
Peanut 92 71 (12.3) 21 (15.9) 0.100 
Cow's milk 77 61 (10.6) 16 (12.1) 0.326 
Sesame seeds 65 50 (8.7) 15 (11.3) 0.158 
Wheat 38 35 (6.1) 3 (2.2) 0.130 
Others 150 126 (21.9) 24 (18.1) 0.933 
              a trigger includes nuts, cashew, pistachio, and tree nuts. 
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4.5.2 Drug Triggers of Anaphylaxis in Qatar 
 
About 103 (17.9%) of anaphylactic cases in Qatar were induced by drugs with 49 
(8.5%) of them rose due to antibiotics such as augmentin (2.7%), penicillin (1.9%),  ceftri-
axone (1.0%) and amoxicillin (0.8%). Other antibiotics such as clarithromycin, cefixime, 
clindamycin, vancomycin, and streptomycin were responsible for 3.3% of anaphylactic 
cases. Within non-steroidal anti-inflammatory drugs (NSAID), anaphylaxis was triggered 
by ibuprofen (4%), followed by paracetamol (1.3%), diclofenac (1.2), aspirin (0.5%). Other 
NSAID such as celebrex and voltaren counted for 0.6% of the anaphylactic cases. Drug 
triggers other than antibiotics and NSAID included intravenous immunoglobulin (4, 0.6%) 
and vaccines (3, 0.5%). Having more than one drug as a trigger of anaphylaxis was noted. 
However, drug triggers contributed insignificantly (P-value = 0.978) for anaphylaxis in 
Qatar (Table 8). 
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Table 8 
Most Common Drug triggers of Anaphylaxis in Qatar, N = 1068 
 
 
Abbreviations: NSAID = Non-steroidal anti-inflammatory drugs 
Triggers All subjects  
N = 1068 
n (%) 
Anaphylaxis 
N = 574 
n (%) 
Allergy 
N= 132 
n (%) 
P-value 
Drugs (All) 123 (11.5) 103 (17.9) 20 (16.2) 0.978 
Antibiotics 58 (5.4) 49 (8.5) 9 (6.8) 0.883 
     Augmentin 19 (1.7) 16 (2.7) 3 (2.2) 1.000 * 
     Penicillin 14 (1.3) 11 (1.9) 3 (2.2) 0.484 * 
     Ceftriaxone 6 (0.5) 6 (1.0) 0 (0.0) 0.596 * 
     Amoxicillin 6 (0.5) 5 (0.8) 1 (0.7) 1.000 * 
         Other antibiotics 22 (2.0) 19 (3.3) 3 (2.2) 1.000 * 
NSAID 36 (3.3) 30 (5.2) 6 (4.5) 0.938 
     Ibuprofen 28 (2.6) 23 (4.0) 5 (3.7) 0.794 * 
     Paracetamol 8 (0.7) 8 (1.3) 0 (0.0) 0.366 * 
     Diclofenac 8 (0.7) 7 (1.2) 1 (0.7) 1.000 * 
     Aspirin 3 (0.3) 3 (0.5) 0 (0.0) 1.000 * 
         Other NSAID  4 (0.3 ) 4 (0.6) 0 (0.0) 1.000 * 
Others 41(3.8) 35 (6.1) 6 (4.5) 0.779 
             * P-value is for Fischer test (exact sig. 2-sided) 
 
 
 
 
4.5.3 Venom Insect Triggers of Anaphylaxis in Qatar 
 
Venom insects’ triggers were associated with 161 (28.0%) of anaphylactic cases 
with 135 (23.5%) of the cases due to black ants. Other venom insects’ triggers such as bee 
(0.5%) and wasp (0.1%) were less common in Qatar. However, unspecified venom insects 
counted for 24 (4.1%) of the cases (Table 9). 
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Table 9 
Most Common Venom Insect Triggers of Anaphylaxis in Qatar, N=1068 
 
Triggers All subjects  
N = 1068 
n (%) 
Anaphylaxis 
N = 574 
n (%) 
Allergy 
N= 132 
n (%) 
P-value 
Venom insects( All) 184 (17.2) 161 (28.0) 23 (17.4) 0.122 
      Black ant 153 (14.3) 135 (23.5) 18 (13.6) 0.101 
      Bee 3 (0.2) 3 (0.5) 0 (0.0) 1.000* 
      Wasp 1 (0.1) 1 (0.1) 0 (0.0) 1.000* 
      Unspecified 29 (2.7) 24 (4.1) 5 (3.7) 0.798* 
                      * P-value is for Fischer test (exact significant 2-sided) 
 
 
 
 
 
4.5.4 Other Triggers of Anaphylaxis in Qatar 
 
Other triggers of anaphylaxis included animals such as cats, horses, and camels, 
followed by grass contact, cold, latex, contrast media, exercise alone and food dependent 
exercise-induces cases. About 44 (7.6%) cases were with idiopathic triggers (Table 10). 
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Table 10 
Other Triggers of Anaphylaxis in Qatar, N =1068 
 
 Triggers All subjects  
N = 1068 
n (%) 
Anaphylaxis 
N = 574 
n (%) 
Allergy 
N= 132 
n (%) 
Idiopathic 49 (4.5) 44 (7.6) 5 (3.7) 
Animal 27 (2.5) 20 (3.4) 7 (5.3) 
Grass contact 10 (0.9) 9 (1.5) 1 (0.75) 
Cold 3 (0.2) 3 (0.5) 0 (0.0) 
Latex 2 (0.1) 2 (0.3) 0 (0.0) 
Contrast media 2 (0.1) 2 (0.3) 0 (0.0) 
Exercise alone 1 (0.1) 1 (0.1) 0 (0.0) 
Food-dependent exercise-induced 1 (0.1) 1 (0.1) 0 (0.0) 
                  * P-value not calculated due to small sample size 
 
 
 
4.6 Common Anaphylaxis Triggers in Relation to Social Demographics 
 
There was a significant difference between the type of anaphylactic trigger and the 
age of the patients. Among the most common triggers of anaphylaxis across age groups; 
food triggered anaphylaxis mainly in children less than 10 years (223, 74.6%) of the cases. 
Drugs and venom insects triggered anaphylaxis more commonly in adults (20 – 55 years) 
than any other age group with 33.1% and 44.0% respectively (Table 11). Among the most 
common triggers of anaphylaxis across gender groups, food triggered anaphylaxis in 63.6% 
of the males while venom insects and drugs induced anaphylaxis in 38.1% and 21.9% of 
the females respectively. There was no significant association between nationality of pa-
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tients and the type of anaphylactic trigger. However, the nationality with the highest per-
centage of anaphylaxis was Qatari followed by non-Qatari Arabs and Asian. Limited num-
ber of anaphylactic cases were idiopathic with no obvious triggers. Within idiopathic ana-
phylaxis, 27 cases were children less than 10 years. The majority patients with idiopathic 
anaphylaxis were males (29, 9.3%). However, no significant association observed between 
idiopathic anaphylaxis across different age, gender, and nationality groups (Table 11).  
 
 
 
Table 11 
Common Triggers of Anaphylaxis in Relation to Social Demographics 
 
Characteristics Anaphylaxis 
N= 574 
n(%)a 
Food Ana-
phylaxis 
N=316  
n(%)a 
Drug Anaphy-
laxis 
N=103 
n (%)a 
Venom Insects 
Anaphylaxis 
N=161  
n(%)a 
Idiopathic  
N=44 
n(%)a 
Age (Years)      
 < 10 Years 300 (77.9) 223 (74.3) 31 (10.3) 48 (16.1) 27 (9.0) 
 10 - 19 Y 109 (83.2) 51 (46.8) 15 (13.8) 40 (36.7) 7 (6.4) 
 20 - 55 Y 137 (86.7) 36 (27.1) 44 (33.1) 59 (44.0) 10 (7.5) 
 > 55 Y 28 (87.5) 6 (21.4) 13 (46.4) 14 (50.0) 0 (0.0) 
P-value  <0.001 <0.001 <0.001 0.334 
Gender      
 Male 315 (79.1) 199 (63.6) 47 (15.0) 63 (20.2) 29 (9.3) 
 Female 259 (84.1) 117 (45.7) 56 (21.9) 98 (38.1) 15 (5.9) 
P-value  <0.001 0.033 <0.001 0.130 
Nationality      
 Qatari 251 (79.9) 137 (55.2) 40 (16.1) 80 (32.3) 15 (6.0) 
 Non-Qatari, Arab 162 (86.6) 86 (53.4) 32 (19.9) 39 (24.2) 14 (8.7) 
 Asian 118 (83.1) 62 (52.5) 21 (17.8) 35 (29.7) 15 (12.7) 
 Others 42 (67.7) 30 (73.2) 10 ( 23.8) 7 (17.1) 0 (0.0) 
P-value  0.117 0.589 0.118 0.333 
     a row percentage 
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The anaphylaxis triggers distribution among different age and gender groups is presented 
in figure 6. 
 
 
 
 
Figure 6. Anaphylaxis triggers distribution among different age and gender groups. 
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4.6.1 Common Comorbidity Factors Associated with Anaphylaxis in Qatar 
 
The comorbidity factors in the study population, and the frequency of anaphylactic 
cases within each comorbidity factor was calculated. Although upper respiratory tract in-
fections were the most common comorbidity factor associated with anaphylactic cases in 
Qatar, the association was insignificant. Asthma (36.2%), atopic dermatitis (33.9%) and 
allergic rhinitis (14.1%) were the most frequent comorbidity factors significantly associ-
ated with anaphylaxis in Qatar (Table 12).  
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Table 12 
Common Comorbidity Associated with Anaphylaxis in  Study Population, N = 1068  
 
Abbreviations: URTI= upper respiratory tract infection, DM = diabetes mellitus, HTN = 
hypertension 
 
Comorbidity factor 
All subjects,  
N= 1068 
n (%) 
Anaphylaxis 
N = 574 
n (%) 
Allergy 
N= 132 
n (%) 
P-value 
URTI 449 (42.1) 240 (41.8) 67 (50.7) 0.064 
Asthma 357 (36.4) 208 (36.2) 68 (51.5) <0.001 
Atopic Dermatitis 326 (33.2) 195 (33.9) 66 (50) <0.001 
Urticaria/Angioedema 254 (25.9) 179 (31.1) 36 (27.2) 0.485 
Gastroenteritis 216 (20.2) 111 (19.3) 31 (23.4) 0.288 
Allergic Rhinitis 142 (14.5) 81 (14.1) 30 (22.7) 0.009 
Otitis 165 (15.5) 74 (12.8) 22 (16.6) 0.257 
Vitamin D deficiency 109 (10.2) 65 (11.3) 17 (12.8) 0.620 
DM 55 (5.2) 41 (7.1) 3 (2.2) 0.370 
HTN 58 (5.4) 40 (6.9) 5 (3.7) 0.176 
Blood disorders 48 (4.5) 30 (5.2) 2 (1.5) 0.064 
Thyroid disease 33 (3.1) 24 (4.1) 3 (2.2) 0.301 
Cardiac diseases 34 (3.2) 22 (3.8) 6 (4.5) 0.708 
Reproductive disorders 28 (2.6) 18 (3.1) 5 (3.7) 0.437 * 
G6PD deficiency 26 (2.4) 16 (2.7) 3 (2.2) 0.511 * 
Sinusitis 16 (1.5) 12 (2.1) 2 (1.5) 0.496 * 
Cancer 11 (1.0) 7 (1.2) 0 (0.0) 0.233 
                                 * P-value is for Fisher test (Exact Sig. 1 sided) 
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4.6.2 Common Comorbidity Factors in Relation to Triggers 
 
The association between anaphylaxis and its trigger within each comorbidity factor 
was variable (Table 13). Food trigger of anaphylaxis was significantly associated with pa-
tients who had asthma (65.5%), atopic dermatitis (71.8%), urticaria/angioedema (63.1%), 
otitis (72.6%), vitamin D deficiency (35.4%), diabetes mellitus (22.0%), hypertension 
(20.0), thyroid disease (25.0%), reproductive disorders (22.2%) and G6PD deficiency 
(87.5%). On the other hand, drugs induced anaphylaxis significantly for patients with 
atopic dermatitis (10.8%), gastroenteritis (7.22%), diabetes mellitus (41.5%), hypertension 
(37.5%), thyroid disorders (50.0%), cardiac diseases (59.1%), and cancer (71.4%). Venom 
insects triggered anaphylaxis mainly in patients who had atopic dermatitis (17.5%), vita-
min D deficiency (50.8%), and reproductive disorders (66.7%). 
 
Notably, Asthma, urticaria/angioedema, otitis, reproductive disorders and G6PD defi-
ciency were significantly associated with food triggers without contribution of the other 
triggers of anaphylaxis. On the other hand, comorbidity factors such as gastroenteritis, 
cardiac diseases and cancer were significantly associated only with drug triggers (Table 
13). 
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Table 13 
Anaphylaxis in Relation to Triggers and Associated Comorbidity 
 
             a row percentage out of anaphylactic cases who had the comorbidity factor 
            $ p-value is for anaphylactic patients within the comorbidity factor with and without the listed triggers  
           * p-value of fisher exact test (Exact sign. 2 sided) 
 
Abbreviations: URTI= upper respiratory tract infection, DM = diabetes mellitus, HTN = hypertension 
 
Comorbidity  
Anaphylaxis 
N = 574 
n (%) 
 Food trigger 
N=316 
Drug triggers 
N=103 
Venom insect triggers 
N= 131 
n  (%)a 
P-value$ 
n (%)a 
P-value$ 
n  (%)a P-
value$ 
URTI 240 (41.8) 135  56.2 0.674 34  14.2 0.37 70  29.3 0.671 
Asthma 208 (36.2) 136  65.4 < 0.001 34  16.3 0.438 46  22.2 0.017 
Atopic Dermatitis 195 (33.9) 140  71.8 < 0.001 21  10.8 <0.001 34  17.5 < 0.001 
Urticaria/Angioedema 179 (31.1) 113  63.1 0.013 28  15.6 0.323 48  27.0 0.674 
Gastroenteritis 111 (19.3) 69  62.2 0.113 8 7.22 <0.001 28  25.2 0.416 
Allergic Rhinitis 81 (14.1) 46  57.5 0.694 16  20 0.613 26  32.5 0.349 
Otitis 74 (12.8) 53  72.6 0.002 10  13.5 0.272 17  23.3 0.304 
Vitamin D deficiency 65 (11.3) 23  35.4 <0.001 11  16.9 0.793 33  50.8 < 0.001 
DM 41 (7.1) 9  22.0 < 0.001 17  41.5 < 0.001 15  36.6 0.224 
HTN 40 (6.9) 8  20.0 < 0.001 15 37.5 0.001 17  42.5 0.039 
Blood disorders 30 (5.2) 12  41.4 0.117 5  16.7 0.834 12  41.4 0.110 
Thyroid disease 24 (4.1) 6  25.0 0.002 12  50.0 < 0.001* 9  37.5 0.309 
Cardiac diseases 22 (3.8) 10  45.5 0.336 13  59.1 < 0.001* 3  13.6 0.118 
Reproductive disorders 18 (3.1) 4 22.2 0.004 3  16.7 1.000* 12  66.7 < 0.001 
G6PD deficiency 16 (2.7) 14  87.5 0.009 1  6.3 0.327* 2  12.5 0.258* 
Sinusitis 12 (2.1) 3  25.0 0.032 1  80.3 0.704* 7  58.3 0.045* 
Cancer 7 (1.2) 2  28.6 0.146 5  71.4 0.003* 1  14.3 0.697* 
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4.7 Common Symptoms of Anaphylaxis in Qatar 
 
 The common symptoms in relation to anaphylaxis summarized (Table 14). The an-
aphylactic patients showed symptoms related to skin (505, 87.9%), respiratory (397, 
69.1%), gastrointestinal (273, 47.5%), cardiovascular (91, 15.8%), and nervous (51, 8.8%) 
systems. Anaphylactic patients with skin related symptoms looked for medical attention 
due to rash (70%), itching (38.6%), urticaria (34.6%), erythema (27.3%), angioedema 
(27.3%), local edema (20.9%), periorbital swelling (12.1%), fever (5.9%) and conjunctivi-
tis (5.2%). Local edema (P-value=0.019) and erythema (P-value=0.058) were statistically 
significant in anaphylactic patients. The major respiratory related symptom that was sig-
nificantly associated with anaphylaxis was dyspnea (44.1%, P-value=0.011). In our study 
cohort, respiratory symptoms such as hoarseness, upper airway obstruction, tachypnea, and 
stridor manifested only in patients with anaphylaxis. In term of gastrointestinal symptoms, 
vomiting was significantly associated with anaphylaxis (31.8%, P-value=0.042). Tongue 
swelling with/without itching, swallowing difficulty, nausea, abdominal pain and diarrhea 
noted only in patients with anaphylaxis. Among patients with anaphylaxis, tachycardia, 
syncope, loss of conscious, cyanosis, bradycardia, and crepitation were the major cardiac 
related symptoms. The most common nervous system related symptom was dizziness 
(5.9%) (Table 14). Fever, which is a constitutional symptom, was common among 34 pa-
tients with anaphylaxis (5.9%). 
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Table 14 
Common Symptoms of Anaphylaxis in the Study Population, N =1068 
Symptoms 
All subjects,  
N= 1068, n (%) 
Anaphylaxis 
N = 574, n (%) 
Allergy 
N = 132, n (%) 
P-value 
Skin-mucosal tissue    564 (52.8)     505 (87.9)          15 (11.3)         0.098 *  
 Rash 434 (40.6) 402 (70.0) 11 (8.3) 0.269 
 Itching 241 (22.5) 222 (38.6) 7 (5.3) 0.835 
 Urticaria 217 (20.3) 199 (34.6) 8 (6.1) 0.524 
 Erythema 173 (16.1) 157 (27.3) 9 (6.8) 0.058 
 Angioedema $ 169 (15.8) 157 (27.3) 5 (3.7) 0.893 
 Lips swelling, +/- itching 78 (7.3) 75 (13.1) 3 (2.2) 0.729 * 
 Tongue swelling, +/- itching 25 (2.3) 21 (3.6) 0 (0.0) 1.000 * 
 Local edema $ 137 (12.8) 120 (20.9) 9 (6.8) 0.019 * 
 Periorbital swelling 78 (7.3) 70 (12.1) 3 (2.2) 0.719 * 
 Conjunctivitis 33 (3.1) 30 (5.2) 3 (2.2) 0.085 
Respiratory     419 (39.2)     397 (69.1)            6 (4.5)          <0.001 *  
 Dyspnea 268 (25.1) 253 (44.1) 3 (2.2) 0.011 
 Cough 138 (12.9) 132 (22.9) 3 (2.2) 0.582 
 Wheezing/Bronchospasm 99 (9.2) 95 (16.5) 1 (0.7) 0.337 * 
 Gasping 69 (6.4) 68 (11.8) 0 (0.0) 0.149 
 Congested oropharynx/nose 52 (4.8) 48 (8.3) 1 (0.7) 1.000 * 
 Rhinitis 38 (3.5) 35 (6.1) 3 (2.2) 0.119 * 
 Hoarseness 23 (2.1) 23 (4.0) 0 (0.0) 1.000 * 
 Upper airway obstruction 17 (1.5) 17 (2.9) 0 (0.0) 1.000 * 
 Tachypnea 17 (1.5) 16 (2.7) 0 (0.0) 1.000 * 
 Stridor 12 (1.1) 12 (2.1) 0 (0.0) 1.000 * 
 Chest pain/tightness 11 (1.0) 9 (1.5) 1 (0.7) 0.254 * 
Gastrointestinal     284 (26.5)      273 (47.5)            5 (3.7)            0.054 
 Vomiting 186 (17.4) 183 (31.8) 2 (1.5) 0.042 
 Abdominal pain 53 (4.9) 53 (9.2) 0 (0.0) 0.401 * 
 Diarrhea 20 (1.8) 20 (3.4) 0 (0.0) 1.000 * 
 Nausea 11 (1.0) 11 (1.9) 0 (0.0) 1.000 * 
 Swallowing difficulty 6 (0.5) 6 (1.0) 0 (0.0) 1.000 * 
Cardiac     94 (8.8)     91 (15.8)            1 (0.7)             0.333* 
      Hypotension     123 (11.5 )     119 (20.7)             2 (1.5)             0.339 
 Tachycardia 35 (3.2) 32 (5.5) 1 (0.7) 1.000 * 
 Syncope/loss of conscious  22 (2.0) 22 (3.8) 0 (0.0) 1.000 * 
 Cyanosis 16 (1.4) 16 (2.7) 0 (0.0) 1.000 * 
 Bradycardia 5 (0.4) 5 (0.8) 0 (0.0) 1.000 * 
 Crepitation 4 (0.3) 4 (0.6) 0 (0.0) 1.000 * 
Nervous system      56 (5.2)     51 (8.8)            2 (1.5)            0.686 
 Dizziness 39 (3.6) 34 (5.9) 2 (1.5) 0.328 
$ Local edema and angioedema are as reported by physicians in the patients’ electronic medical records. 
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4.7.1 Common Anaphylaxis Symptoms of the Patients’ Cohort in Relation to the Trig-
gers 
 
Symptoms of anaphylaxis were variable. For anaphylaxis triggered by food, the 
symptoms were related to gastrointestinal (71.1%, P value < 0.001), cardiac (28.6%, P 
value < 0.001), and nervous (37.3%, P value=0.005) systems, which was statistically sig-
nificant (Table 15). However, the anaphylaxis triggered by drugs was significant in asso-
ciation with skin (16.4%, P value=0.003) and cardiac (34.1%, P value < 0.001) manifesta-
tions.  Venom insect triggers were significantly associated with symptoms related to gas-
trointestinal (15.8%, P value <0.001) and nervous systems (45.1%, P value = 0.003) (Table 
15). 
 
 
Table 15 
Anaphylaxis Symptoms in Relation to Triggers and Organ Systems, N = 574 
 
Symptoms Anaphylaxis 
N= 574 
n (%) 
Food triggers 
N = 316 
Drug triggers 
N = 103 
Venom insect triggers 
N =131 
n (%)a P-value$ n(%)a P-value$ n(%)a P-value$ 
Skin  505 (87.9) 281(55.6)  0.947 83 (16.4) 0.002 144 (28.6)  0.006 
Respiratory 397 (69.1) 214(53.9) 0.163 70 (17.6) 0.952 119 (30.1) 0.014 
Gastrointestinal 273 (47.5) 194 (71.1) < 0.001 40 (14.7) 0.061 43 (15.8) < 0.001 
Cardiac 91 (15.8) 26 (28.6) < 0.001 31 (34.1) < 0.001 27 (29.7) 0.567 
Nervous  51 (8.8) 19 (37.3)  0.005 14 (27.5) 0.055 23 (45.1) 0.003 
   a row percentage out of anaphylactic cases who manifested the concerned symptoms 
   $ p-value is for anaphylactic patients within the concerned symptoms with and without the triggers  
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4.7.2 Common Anaphylaxis Symptoms in Relation to Dispensed EAIs 
 
EAI dispensed in Qatar to treat anaphylactic symptoms that were related to skin(445, 
89.1%), respiratory (349, 69.9%), gastrointestinal (235, 47.1%), cardiac (63, 12.6%), and nerv-
ous (41, 8.2%) systems. No EAIs dispensed for 74 anaphylactic cases, of which skin, respira-
tory, gastrointestinal, cardiac, and nervous-related symptoms were present as 79.7%, 64.8%, 
51.3%, 37.8%, and 13.5%, respectively. Based on status of anaphylaxis and EAI, the study 
population was divided into four groups: (i) anaphylactic patients with dispensed EAI, (ii) an-
aphylactic patients without dispensed EAI, (iii) patients without anaphylaxis and had dispensed 
EAI, (iv) patients without anaphylaxis nor dispensed EAI. The latest group had only ten pa-
tients with no symptoms (not shown in Table 16). Significant difference observed for the symp-
toms of the other three groups, especially in term of respiratory- and cardiovascular- (P value 
< 0.001) and skin- (P value 0.008) related symptoms (Table 16). 
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Table 16 
Anaphylaxis Symptoms in Relation to Dispensed EAIs, N = 555 
 
Symptoms 
EAI (+) 
Anaphylaxis (+) 
N = 499 
n (%) 
EAI (+) 
Anaphylaxis (-) 
N = 118 
n (%) 
EAI (-) 
Anaphylaxis (+) 
N = 74 
n (%) 
P-value 
     
Skin 445 (89.1) 15 (12.7) 59 (79.7) <0.001 
Respiratory 349 (69.9) 6 (5.1) 48 (64.8) < 0.001 
Gastrointestinal 235 (47.1) 5 (4.2) 38 (51.3) 0.175 
Cardiac 63 (12.6) 1 (0.8) 28 (37.8) <0.001 
Nervous  41 (8.2) 2 (1.6) 10 (13.5) 0.545 
            There were ten patients with no symptoms within EAI (-) and (-) anaphylaxis group (not shown) 
 
 
 
4.8 Patients’ Outcome in Relation to EAIs Compliance 
 
Patients with anaphylaxis treated using three approaches: 294 patients (51.2%) 
treated by EAIs in combination to other drugs, 143 patients (24.9%) treated with other 
drugs without EAIs while 97 patients (16.8%) treated exclusively with EAIs. Out of 574 
patients diagnosed with anaphylaxis, only 22 patients (3.8%) had serious adverse events. 
Patients treated with drugs other than EAIs at the time of the anaphylactic episode had 
more serious adverse events (n=10, 7.0%). Incidents of two deaths and one shock occurred 
in patients where no EAI used (Table 17). 
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Table 17 
Patients’ Outcome of Anaphylaxis in Relation to EAIs 
 
  Anaphylaxis Anaphylaxis cases Treated by    
Patients outcome Yes 
Epinephrine (+)  
other drugs (-) 
Epinephrine (-)  
other drugs (+)  
Epinephrine (+)  
other drugs (+) 
 
 N =574 N =97 N =143 N = 294  
  n (%) n (%) n (%) n (%) P-value 
Serious Adverse Event 22 (3.8) 2 (2.1) 10 (7.0) 8 (2.7) 0.053 
      Respiratory arrest 5 (0.9) 1 (1.0) 2 (1.4) 2 (0.7) * 
      Profound hypotension 3 (0.5) 1 (1.0) 1 (0.7) 1 (0.3) * 
      Cardiac arrest 2 (0.3) 0 (0.0) 1 (0.7) 1 (0.3) * 
      Death 2 (0.3) 0 (0.0) 2 (1.4) 0 (0.0) * 
      Endotracheal intubation 10 (1.7) 1 (1.0) 4 (2.8) 4 (1.4) * 
     Pulmonary edema 9 (1.6) 0 (0.0) 5 (3.5) 3 (1.0) * 
     Infection 2 (0.3) 0 (0.0) 0 (0.0) 2 (0.7) * 
     Shock 1 (0.2) 0 (0.0) 1 (0.7) 0 (0.0) * 
 * P-value not calculated due to small sample size 
 
 
 
Admission of patients with anaphylaxis to the health care facilities was statistically 
significant among the three treated groups. The majority of patients were admitted to ED 
(n =360) and discharged within the same day (n=253). Patients treated with both EAIs and 
other drugs had more admission than the other two groups. Interestingly, the lowest inpa-
tient and ICU admission was for patients treated with EAIs alone (Table 18).  
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Table 18 
Admission of Patients with Anaphylaxis in Relation to EAIs 
 
Abbreviations: ED = emergency department, LOS = length of stay, A/I = allergy and immunology 
  
Anaphylaxis 
Anaphylaxis cases Treated by 
 
Patients outcome Yes 
Epinephrine (+) 
other drugs (-) 
Epinephrine (-) 
other drugs (+)  
Epinephrine (+)  
other drugs (+) 
 
 N =574 N =97 N =143 N = 294  
  n  n (%)a n (%)a n (%)a P-value 
ED admission 360  51 (14.2) 82 (22.8) 221 (61.4) < 0.001 
ED LOS, n =372      
                  < 24 hours 253  46 (18.2) 51 (20.2) 153 (60.5) < 0.001 
                 24 -72 hours 71  5 (7.0) 18 (25.4) 47 (66.2)  
                 > 72 hours 39  1 (2.6) 14 (35.9) 22 (56.4)  
Referral to A/I clinic 293  70 (23.9) 70 (23.9) 134 (45.7) < 0.001 
Inpatients admission 71  2 (2.8) 10 (14.1) 58 (81.7) < 0.001 
ICU admission 11 0 (0.0) 5 (45.4) 5(45.4) * 
Discharged against advice 6  1 (16.7) 2 (33.3) 3 (50.0) * 
    a row percentage 
   * P-value not calculated due to small sample size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
CHAPTER 5: DISCUSSION 
 
In this study, we examined EAIs dispense as a possible indicator for the frequency 
of anaphylaxis in Qatar; therefore, we pulled out the ICD-10 codes of anaphylaxis and 
EAIs dispense records from HMC Cerner system and we obtained 1,068 electronic medical 
records during the period 2012-2016. We reviewed each EMR for EAIs dispense and phy-
sician diagnosis of anaphylaxis and classified anaphylaxis triggers according to age, gen-
der, nationality, and co-morbidity factors. In addition, we compared the clinical outcomes 
of patients treated with and without EAIs.  We identified 739 patients with EAIs dispense, 
of whom 574 patients were diagnosed with anaphylaxis (Tables 2, 4). The sensitivity of 
detecting the cases of anaphylaxis by EAIs was 87.0% with PPV of 80.0%. However, the 
specificity (8.0%) was low (Figure 5). The female/male ratios were higher with predomi-
nance among the children (Figure 6). The main triggers were Food, insect stings, and drugs 
(Table 7 - 8). The associated atopic diseases among our patients’ cohort were mainly 
asthma, atopic dermatitis, and allergic rhinitis (Table 12). Unfortunately, EAIs records 
were not available for 74 patients (Table 6). Additionally, 143 patients treated using alter-
native drugs in discordance to the international and local guidelines of anaphylaxis man-
agement (Table 17), consistent with the serious adverse events among patients that were 
treated without EAIs. This study is expected to serve as a guide for clinicians and health 
care professionals in Qatar in allergy clinics.  
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5.1 Dispensed EAIs as an Indicator Tool to Estimate Anaphylaxis 
 
Our data showed that over a period of four years from 2012 to 2016, 739 patients 
had EAIs dispense, 574 patients were with anaphylaxis; of which, 499 patients had EAIs 
dispense while 74 patients had no EAIs dispense at the time of their discharge (Table 3, 4, 
5).  The sensitivity of using the EAIs dispense was 87.0% with PPV of 80% (Figure 5). 
Such high sensitivity of EAIs dispense to detect anaphylaxis might be due to HMC ana-
phylaxis guidelines which demand that EAIs should be provided for patients who were 
exposed to an anaphylactic episode at the time of their discharge as a long-term care plan. 
The specificity of EAIs dispense was low (8.0%) with NPV of 11.0% (Figure 5). Many 
reasons could explain this finding. First, a considerable cohort of patients were diagnosed 
with merely allergic condition (n=132, 12.3%); of which 118 patients had EAIs, ten pa-
tients had no EAIs and four had incomplete charts (Table 6). Secondly, patients who were 
non-anaphylactic, most likely received EAIs as a prophylactic measure.  These patients 
might be thought to be at high risk of developing anaphylaxis due to their strong history of 
other atopic disorders such as asthma (n=68, 51.5%), atopic dermatitis (n=66, 50.0%), ur-
ticaria (n=36, 27.2%), and allergic rhinitis (n=30, 22.7) (Table 12). Such similar strong 
history of atopy observed in patients with anaphylaxis (Table 12) and this similarity might 
create difficulties in the ability of physicians to distinguish between anaphylaxis and non-
anaphylaxis conditions, and would influence the physicians’ decision to prescribe EAIs for 
non- anaphylactic cases. Third, the indication of EAIs dispense for these non-anaphylactic 
cases was valid which highlighted that EAIs dispense is a potential medication for some 
non-anaphylactic cases (Table 5). Therefore, EAIs dispense was unable to correctly clas-
sify non-anaphylactic cases and showed low specificity.  
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Combining research methods in our study to detect anaphylaxis was crucial to es-
timate anaphylaxis frequency since none of the methods estimated anaphylaxis correctly 
on individual basis. For instance, using EAIs dispense in combination with the ICD-10 
codes of anaphylaxis enabled us to capture 74 patients with anaphylaxis, which we could 
not capture using EAIs dispense method alone (Table 6). Additionally, using EAIs dispense 
as the sole indicator to estimate anaphylaxis would result in overestimation due to its low 
specificity and require critical review of patients’ medical records. These two observations 
are important observations for clinical research in this field. Previous studies used EAIs 
dispense as a surrogate approach to study anaphylaxis   (100-106).  In an epidemiological 
study, Simons et al. (2002), found that 0.95% of the population had epinephrine dispensing 
in Manitoba province, Canada over a period of five years (1995 -2000) and accordingly 
estimated anaphylaxis rate as 954 per 100,000 persons (101). A different study from Israel 
showed that the total rate of EAI dispensing increased by 76% from 1997 to 2004 (102). 
However, this study, unfortunately, was not inclusive to estimate anaphylaxis rate and it 
discussed only food allergy and asthma (102). Motosue et al. (2017), reported that EAIs 
dispense rate among pediatrics had a similar percentage of food-induced anaphylaxis in the 
United States over a period of nine years (2005 – 2014) and both increased by approxi-
mately 16.0% (106). Another retrospective study over six years period (1999 – 2004) esti-
mated a low prevalence of anaphylaxis among Singapore population and characterized an-
aphylaxis based on EAIs dispense records (105).  However, none of these studies calculated 
sensitivity, specificity, positive and negative predictive values of EAI dispense as we did 
(Figure 5). To our knowledge, this is the first study that calculates the sensitivity and PPV 
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in these settings; therefore, our findings indicate that using EAIs dispense to estimate the 
frequency of anaphylaxis in a large cohort of patient is a potential sensitive method to 
indicate the number of patients with anaphylaxis, but need to be used in combination with 
other methods not to miss or overestimate anaphylactic cases. These findings have im-
portant application in clinical practice and research. 
 
5.2 Anaphylaxis Triggers in Relation to Patients’ Demographics in Qatar 
 
The distribution of anaphylaxis among different age and gender groups is variable 
in Qatar (Figure 6). Our data showed a predominance of anaphylaxis among pediatrics (n 
=300, 77.9%) (Table 2); which is reasonable since, at a single time point, anaphylaxis ini-
tially diagnosed at childhood and relevant triggers avoidance recommended as preventive 
measures of a long-term action plan and risk reduction. However, such avoidance measures 
are neither easily nor strictly followed by children of this age group (68, 84, 107). In this 
study, we found that anaphylaxis was common among male children (n = 224, 39.0%) and 
female adults (n=114, 19.8%) (Figure 6); a finding that is consistent with other Qatari stud-
ies in which the incidence of anaphylaxis was common among pediatric males (69.0%) and 
adult females (78.0%) (4, 5). This variation probably attributed to the sample size differ-
ence in each study (4, 5). Several studies around the world showed similar distribution of 
anaphylaxis among different age and gender groups. A population-based epidemiological 
study of emergency department visits in Florida reported that the highest anaphylaxis inci-
dence rate was among the youngest males (8.2/100,000 visits) and the adult females 
(10.9/100,000 visits) (48). Similar to that, findings of Rochester epidemiology project from 
1990 through 2000 showed that age-specific incidence rate of anaphylaxis was the highest 
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for ages 0 -19 years (51). In contrast, anaphylaxis among UK critical care units between 
2005 and 2009 reported higher admissions among adults than children (60). However, such 
variation might be related to the higher number of participated female adults (65%) in this 
study (60).  
 
In our patients’ cohort, we observed that the association between anaphylaxis and 
the national origin was statistically significant (P= 0.009), Qataris (43.7%), non-Qatari 
Arab (28.2%) and Asian (20.5%). Such considerable variation can be due to the difference 
of the genetic makeup of Qatar population as the structure of Qatar community is a melting 
pot of hundreds of nationalities of migrant workers that have different genetic predisposi-
tion to Allergy and anaphylaxis, consistent with the ethnic variations of anaphylaxis. In 
general, anaphylaxis was common (42, 48, 49, 51, 53), more associated with repeated use 
of epinephrine (108) and more fatal (56) among Caucasians compared to Black, La-
tino/Hispanic and Asian ethnicities. In contrast, Mahdavinia et al. (2017) reported that Cau-
casians had a lower rate of food allergy associated anaphylaxis than African American and 
Hispanic children and demonstrated ethnicity differences of food allergen profiles, coex-
istent atopic condition and clinical outcome (109). Additionally, Buka et al. (2015) reported 
that Caucasians had less incidence, and less likely to present with severe anaphylactic 
symptoms than South Asian British children living in Birmingham (110). Unfortunately, 
such ethnicity correlation lack in Arabic studies and there is no ethnicity nor anaphylaxis 
registry in Qatar. Therefore, our data might provide the baseline for assessing future trends. 
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5.3 The Profile of Anaphylaxis Triggers in Qatar 
 
Our results showed that food was the major trigger of anaphylaxis in Qatar and 
affected mainly children less than ten years (Figure 6A). The main allergen triggers of 
food-induced anaphylaxis were nuts and eggs (Table 7), a finding that was consistent with 
a Saudi study reported in 2015 (70). Peanuts, a significant trigger of food-related anaphy-
laxis in the United States (42, 53, 55), ranked in the fourth position after seafood in Qatar 
(Table 7). In a prospective cohort study conducted in Qatar from 2007 to 2010, cow's milk 
proteins anaphylaxis found in ten children out of 38 subjects and camel milk suggested as 
being a safer alternate choice (3, 64). With a larger study population, anaphylaxis induced 
by cow's milk accounted for 61 cases (10.6%) from 2012 to 2016 (Table 7). In comparison, 
cow's milk protein anaphylaxis resulted in 6-9 % of children hospital admission in the USA 
(42, 47, 49). It induced 10% of anaphylactic reactions in the UK (111) where eight children 
fatalities occurred during the period from 1992 - 2012 (38). Our data showed that sesame 
seed accounted for 8.7% of anaphylaxis cases in Qatar (Table 7).  However, as a global 
allergen, sesame seed is affecting approximately 0.1% of  North American population and 
is the third common food allergen in Israel (112).  In Lebanon, a cross-sectional study 
showed that allergic reactions triggered by sesame seed were of severe grade and mani-
fested mainly in the form of anaphylaxis (81). This study suggested that the sesame seed 
is the "Middle Eastern" peanut (81).  
  Anaphylaxis and allergic reactions attributable to Hymenoptera stings in our study 
demonstrated predominance in female adults (n = 50, 45.9%) and male children (n = 30, 
40.0%) (Figure 6B). Interestingly, 135  patients (23.5%) developed anaphylaxis by the 
sting of black ants (Table 9); which are widespread ants in tropical Africa and the Middle 
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East and is a native insect in Arabian desert countries including Qatar (113, 114). Allergic 
reactions due to black ant stings range from pain with local itching at the sting site to severe 
anaphylactic shock. AlAnazi et al. (2009) showed a diversity of manifestation and human 
response to black ant stings in four cases encountered in Al Riyadh, the capital city of Saudi 
Arabia, and three patients were adult females (115). In contrast to our findings, lower prev-
alence of black ant induced anaphylaxis reported in Saudi Arabia (3.2%) (70), and Singa-
pore (12.9%) (116). The unreported incidence of black Samsum ant induced anaphylaxis 
recognized in Iran where most stings resulted in mild allergic reactions (117). However, in 
United Arab Emirate, four deaths were recorded after the sting of this ant (118). Several 
studies attribute diversity of symptoms to the antigenicity variation of black ants' toxin 
composition according to geographical regions (117, 119). Anaphylaxis in Najran, a city 
in southwestern Saudi Arabia, was triggered by a different species of black ant, Solenopsis 
Richteri, in non-Saudi expatriates (1997 -1999) (120).  A Turkey retrospective review de-
fined prevalence of Hymenoptera stings anaphylaxis among adult patients, however, the 
causative triggers were mainly honey bees and different wasp species (85). In contrary to 
Qatar, the later Turkish study showed a predominance of Hymenoptera induced anaphy-
laxis among male adults (57.1%) (85). In light of the absence of studies published about 
black ant abundance, distribution, and its toxin antigenicity in Qatar, our results flag it as 
a public health hazard in Qatar owing to its strong association with anaphylaxis. Addition-
ally, black ant immunotherapy is not available in Qatar. Thus, we would recommend inte-
grating entomology, bioecology and medicine points of view in future studies.   
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5.4 Co-morbidity Factors of Anaphylaxis in Qatar 
 
Our findings indicate that Asthma (p<0.001), atopic dermatitis (p<0.001), and al-
lergic rhinitis (p=0.009), were the main comorbidity factors that were significantly associ-
ated with anaphylaxis in Qatar (Table 12). Anaphylaxis was common in 208 patients with 
asthma (36.2%), 195 patients with atopic dermatitis (33.9%), and 81 patients with allergic 
rhinitis (14.1%) (Table 12). These observations might be explained by a recent concept 
called “atopic march”, which suggested that atopic disorders are related to each other and 
coexist in sequential manner throughout the patient life (121, 122). Several studies reported 
similar association of atopic disorders among patients with anaphylaxis and visualized such 
association as a risk factor that might worsen the prognosis of the anaphylactic episodes, 
boost their severity grade, and their recurrence probability (4, 5, 47, 49, 51, 89, 116, 123, 
124). Figure 7 provides summary of these previous studies. Among patients with anaphy-
laxis, asthma was the most common atopic disorder in Qatar and USA and the second most 
common atopic disorder among patients in Turkey, Singapore, Thailand and Latin America 
(Figure 7). However, allergic rhinitis was the most frequent atopic disorder among patients 
with anaphylaxis in Turkey, Singapore, Thailand and Latin America (figure 7) Although 
we have reported the co-existing of allergic rhinitis with anaphylaxis in our patients’ co-
hort, none of the two presented Qatari studies reported its co-existing (Figure 7). On the 
other hand, atopic dermatitis was the second most frequent atopic disorder among patients 
with anaphylaxis in Qatar and USA and the least frequent disorder reported by the other 
studies in Turkey, Thailand and Latin America (Figure 7). Knowing this association of 
atopic disorder among patients with anaphylaxis is important for clinicians to ensure timely 
therapeutic plan and proper management of the patients.  
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Figure 7. Summary of Atopic disorders among patients with anaphylaxis in the studies (4, 5, 45, 
47, 49, 87, 114, 121, 122) 
 
 
We reported family history of atopy and anaphylaxis in 63 patients (Table 3). Hav-
ing positive family history of atopy among patients with anaphylaxis suggest presence of 
common genetic, epigenetic, and environmental factors (7, 122, 125). These factors might 
interact with each other in a yet unclear manner to influence the patients' predisposition 
toward development of more severe allergic reactions (anaphylaxis).  
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In our patients' cohort, there was a statistically significant association between co-
morbidity factors and categories of anaphylaxis triggers (Table 13). For instance, statisti-
cally significant association of atopic dermatitis observed with all the classes of anaphy-
laxis triggers (P<0.001) (Table 13). This finding might be because the loss of skin barrier 
integrity in atopic dermatitis facilitates easy penetration of food as well as environmental 
allergens and subsequent enhancement of allergy (121, 126). In our study, asthma showed 
statistically significant association with food triggers (P <0.001) and 65.4% of patients with 
asthma had food induced anaphylaxis (Table 13). For a long time, scientists thought that 
asthma triggered exclusively by environmental inhalant allergens. However, the associa-
tion of asthma with food allergy alters this current concept to suggest that food allergens 
might play a role in the pathogenesis of asthma by a not yet fully understood mechanism 
(121). A recent Qatari study linked the prevalence of asthma among Qatar children (19.8%) 
to the increased construction and poor air quality in the last decades which highlights a role 
of environmental inhalant allergens (127). Another Qatari cross-sectional study showed 
that food allergy and positive family history were a significant predictor of asthma in Qatar 
(128). Several studies emphasized that the severe form of food allergy, anaphylaxis, was 
common among children with asthma (44, 49, 65, 123) and the hazard of anaphylaxis shock 
was as high as 5.2 fold in patients with asthma (129). Interestingly, finding such association 
between asthma and food triggers of anaphylaxis in our study might serve as a base for 
further researches to figure out the role of gut microbiota in the pathogenesis of asthma, a 
field of growing interest in the scientific world. Moreover, our study is the first one in Qatar 
that correlates these atopic disorders with the different categories of anaphylaxis triggers.  
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5.5 Patients’ Clinical Outcomes in Relation to EAIs therapy 
 
Clinical findings of patients’ symptoms.  
 
Patients’ clinical outcomes were emphasized by assessing the clinical manifestation 
of anaphylaxis. We found that symptoms included cutaneous (n=505, 87.9%), followed by 
respiratory (n=397, 69.1%), gastrointestinal (n-273, 47.5%), cardiac (n=91, 15.8%) and 
neurological (n=51, 8.8%) (Table 14). This order of anaphylactic symptoms’ distribution 
was similar in term of cutaneous and respiratory symptoms in several studies around the 
world, however, there was slight variability in term of gastrointestinal, cardiac and neuro-
logical symptoms (Figure 8) (5, 49, 59, 85, 123).  
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Figure 8. Summary of symptoms among patients with anaphylaxis in the studies (5, 49, 
59, 85, 123) 
 
 
Local edema (P=0.019), erythema (P=0.058), dyspnea (P=0.011), and vomiting 
(P=0.042) were significantly different among patients with anaphylaxis and allergy in Qa-
tar (Table 14). Similar to our study, two retrospective studies found that dyspnea and vom-
iting were significantly different among patients with anaphylaxis and allergy in USA (47, 
49). In our patients’ cohort, some symptoms manifested in patients with anaphylaxis rather 
than allergy. These symptoms include hoarseness, upper airway obstruction, tachypnea, 
stridor, gasping, abdominal pain, tongue swelling/itching, diarrhea, nausea, swallowing 
difficulty, tachycardia, syncope, and cyanosis (Table 14). However, we found that these 
symptoms were not limited for patients with anaphylaxis since several studies reported 
them among allergic patients (47, 49).  
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The involvement of organ systems during anaphylaxis episodes was significantly 
different based on the type of triggers (Table 15).  Gastrointestinal, cardiac and nervous 
symptoms were significantly associated with food triggers of anaphylaxis while only gas-
trointestinal and nervous symptoms showed statistically significant association with in-
sects’ stings (Table 15). Skin and cardiac symptoms showed statistically significant asso-
ciation with drug triggers of anaphylaxis (Table 15). These findings might serve as a clin-
ical guide for clinicians to predict the type of trigger of anaphylaxis based on the patients' 
symptoms. Such immediate recognition and sub-sequent identification of the anaphylactic 
trigger are the most critical aspects to ensure patient safety, and it would assist physicians 
to set up management plans for anaphylaxis triggers avoidance in future.  
 
Clinical outcomes of patients.  
 
Another part of the assessment of patient's clinical outcome is the evaluation of the 
benefits, and harms of therapeutic options and comparing them. In our study, patients were 
treated with three different therapeutic approaches either with epinephrine (n=97, 16.8 %), 
alternative drugs to epinephrine (n=143, 24.9%), or both (n=294, 51.2%) (Table 17). Inter-
estingly, treating 143 patients (24.9%) without epinephrine use reflected a critical gap in 
the management of patients with anaphylaxis and raised concern on the physicians’ com-
pliance to the international guidelines and HMC policies to manage those patients (Table 
17). Using alternative medications such as antihistamines in replacement of epinephrine is 
risky since antihistamines have slow absorption and require 1-3 hours for maximum plasma 
concentration after oral administration (25); while intramuscular injection of epinephrine 
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requires eight minutes only to reverse anaphylactic symptoms and relieve the patients’ dis-
tress (25, 96). Moreover, antihistamines do not reverse upper air-way obstruction and hy-
potension (29). Accordingly, this group of patients had more clinically significant conse-
quences such as serious adverse events (n =10, 7.0%), pulmonary edema (n=5, 3.5%), en-
dotracheal intubation (n=4, 2.8%), respiratory arrest (n=2, 1.4%), and cardiac arrest (n=1, 
0.7%) compared to patients treated with epinephrine alone (n=97, %) (Table 17). The in-
cident of two deaths and one shock occurred among patients treated without epinephrine 
(Table 17). A recent study showed a dependence of ED clinicians on antihistamine drugs 
as first-line treatment of anaphylaxis for adults in Qatar (4, 5). Therefore, our finding raised 
real concern about the clinical practice of anaphylaxis management in Qatar. 
 
Similar to Qatar, the frequent use of alternative drugs rather than epinephrine to 
treat anaphylaxis is common in other parts of the world. For instance, A multi-center ret-
rospective case study of Turkish children during the period from 1999 to 2009 showed that 
out of 158 anaphylactic episodes, 148 (93.7%) received antihistamines while 51 (23.3%) 
received epinephrine (123).  A retrospective study of EAIs re-fill adherence in primary care 
centers in Manitoba, Canada between 2012 and 2014 showed that odds of EAIs re-fill pre-
scription were inversely related to non-EAI medications re-fill (130). Our finding might 
highlight improper practice of physicians since the evidence base of using epinephrine to 
treat anaphylaxis is level B recommendation and is stronger than using antihistamine (level 
C recommendation) (25, 29). All international guidelines from World Allergy Organization 
(WAO), American Academy of Allergy, Asthma and Immunology (AAAAI), and Euro-
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pean Academy of Allergy and Clinical Immunology (EAACI) recommended antihista-
mines as adjunctive therapy to treat anaphylaxis and indicated that its action is inferior to 
epinephrine (8). However, our finding might be a matter of under-recognition when ana-
phylaxis encountered for the first time in these patients and followed by proper manage-
ment once recognized by physicians and this is supported by having EAI dispensed for 499 
patients with anaphylaxis (87.0%) (Figure.5).This finding reflects the need to educate and 
train physicians regarding the recognition and treatment of anaphylaxis. 
 
5.6 Compliance toward Dispensed EAIs for Anaphylaxis Therapy 
 
Having dispensed EAIs as first aid measure to manage accidental exposure to ana-
phylaxis triggers is important and critical for long-term management plan of anaphylaxis. 
In our study, we found that EAIs dispensed for 499 patients (75.7%) with anaphylaxis, 
which is good clinical practice (Table 6). However, 72 patients (10.5%) had no dispensed 
EAIs (Table 6). This finding is crucial, and requires attention from clinicians in Qatar since 
it indicates that these 72 patients (10.5%) left unprotected. Moreover, in our patients’ co-
hort, 92.5% of anaphylactic events occurred in community setting, and 233 patients (33.0 
%) had recurrent anaphylactic episodes, which indicates that the probability to have ana-
phylaxis in community setting is high.  (Table 3). Interestingly, only 19.2% of patients 
made actual use of the EAIs (Table 5). Such low compliance of EAIs reported in different 
regions of the world. A UK prospective questionnaire study stated that out of 245 patients 
with anaphylaxis, only 41 patients (17%) used EAIs (131). The rest 204 patients (83.0%) 
did not use it although they suffered from potentially life-threatening symptoms of anaphy-
laxis (131).  This was due to various reasons: 54.4% thought it was unnecessary, 7.8% 
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waited for ambulance arrival, 5.4% had no EAI device at the anaphylaxis episode time, 
2.5% were too scared to use it, 2.5% were not trained or had an expired one (131). Similar 
low compliance to EAIs reported among Victorian governmental schools in Australia 
where the annual usage rate of EAIs activated per 1000 school students at risk of anaphy-
laxis ranged from 6 to 8 per year (132). Such low compliance might reflect either the failure 
to use these devices when needed or the successful strict risk minimization plans within 
the school settings (132). In our study, we were not able to figure out whether the EAIs are 
underutilized or it is a matter of under-reporting of EAIs usage by the physicians. Further 
studies are urgently needed to assure justifiable reasons for such low compliance in Qatar 
and to determine the cost-effectiveness of EAIs dispense against its usage in the commu-
nity to protect patients’ lives.  
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
CHAPTER 6: CONCLUSION 
 
In this study, we reviewed 1068 electronic medical records to assess EAIs as a clin-
ical indicator of anaphylaxis; shedding light on anaphylaxis triggers, co-morbidity factors, 
symptoms and patients’ clinical outcomes in Qatar for a period of four years (2012 -2016). 
We quantified 574 patients with anaphylaxis and found that EAIs dispense is a highly sen-
sitive method to estimate anaphylaxis, but its relatively low specificity means that it will 
be falsely positive for some patients who actually had no anaphylaxis. Therefore, as a clin-
ical indicator, it should be used with care to avoid overestimation of anaphylaxis.  
Nuts and black ants were the most common trigger of anaphylaxis in Qatar. Atopic disor-
ders such as asthma, atopic dermatitis and allergic rhinitis were the common comorbidity 
factors.  Our study showed that 143 patients with anaphylaxis were treated with drugs other 
than epinephrine as first line of intervention, which highlighted a critical gap of anaphy-
laxis management in Qatar.  The current study can be used as a clinical guide for allergy 
clinics and serves as a baseline to assess future trends of anaphylaxis in Qatar. 
 
6.1 Strengths and limitation  
 
A key strength of this study is that Hamad General Hospital, a member of Hamad 
Medical Corporation, is the only medical facility that dispenses epinephrine auto-injector 
in Qatar. Therefore, using dispensed epinephrine auto-injector records of “outpatients” in 
combination with medical coding system (ICD-10AM) of anaphylaxis of “inpatients” re-
flected the frequency of anaphylaxis overall Qatar.  
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We sought to obtain EAI dispense from pharmacy department for the same period 
of ICD-10 codes of anaphylaxis for inpatients (2012 – 2016). However, it was not possible 
to pull out patient identification numbers from HGH outpatient pharmacy for the same 
period because limitations of the software itself. In addition, Cerner software was not alive 
for HGH pharmacists before 2016. Therefore, dispensed EAIs records from HGH outpa-
tient pharmacy was available for one year only (January – December 2016). However, 
using “Cerner power chart” to review the EMRs of the one year pulled list included data 
of EAIs dispense of previous years since EAIs are “refill drugs” and the eldest EAIs dis-
pense in the EMRs of this subset dated in 2007.  
 
Limitations of this study owing to its retrospective nature and the possibility of 
misreporting and underreporting of cases. Therefore, our reported results should be care-
fully interpreted “within the boundary of available data” in the electronic medical records 
of Cerner system. 
 
6.2 Recommendation for Future Studies 
 
We believe that changing the direction of anaphylaxis studies from the health care 
setting to the community setting will provide better care of anaphylaxis cases for two rea-
sons. First, the majority of anaphylaxis episodes occur in the community. Second, compli-
ance to international guidelines is not optimum in clinical setting; therefore, the sensitivity 
of any selected research tools to identify patients with anaphylaxis will be affected.  
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We suggest establishing a national registry system of atopic disorders, especially 
asthma and anaphylaxis in parallel with ethnicity and geographical areas to monitor the 
trend of these diseases in Qatar, and to carry out genetic and molecular studies to under-
stand and differentiate the genetic makeup of our population in relation to other ethnic 
groups. Such understanding may enhance the implantation of personalized medicine in fu-
ture and improve the quality of life of those patients. Having children less than ten years 
being the majority affected patients by these disorders worth such effort. 
 
An exciting area of research would be studying the antigenicity of black ant toxins 
in Qatar, identifying the black ant species that induce anaphylaxis correctly and developing 
customized immunotherapies to the patients in Qatar.  Such research would require inte-
gration of knowledge from different disciplines of research, including, chemistry, entomol-
ogy, bio-ecology, pharmacology and medicine. 
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